^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Solid Tumor
    Drug:PF-08046054 (Microtubule inhibitor, PD-L1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of SGN-PDL1V in Advanced Solid Tumors

    Excerpt:
    ...- Participants must have PD-L1 expression based on historical testing...
    Trial ID:
    SGNPDL1V-001
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2021
    Title:

    783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors

    Published date:
    11/09/2021
    Excerpt:
    SGN-PDL1V cytotoxicity was evaluated using PD-L1 expressing tumor cell lines in vitro and xenograft tumor models in vivo….In vivo, SGN-PDL1V achieved tumor regressions in multiple tumor xenograft models at doses as low as 1 mg/kg when dosed weekly for a total of three doses.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.783